Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib in Axial Spondyloarthritis
NCT03190603Phase 4Completed
- Sponsor
- Armed Forces Capital Hospital
- Start
- Jun 2018
- Primary completion
- Jun 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of celecoxib in axial spondyloarthritis (axSpA), sponsored by Armed Forces Capital Hospital. Primary endpoint: Spondyloarthritis Research Consortium of Canada MRI score at 12 weeks. Started Jun 2018; status: completed.
02
Drugs
celecoxib
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on NCT03190603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03190603.